In contrast, the NF-κB inhibitor pyrrolidine-dithiocarbamate was less synergistic with olaparib, whereas sitagliptin used to treat type II diabetes had no effect, in line with its failure to induce robust expression changes. Here, NFKB1 is linked to type 2 diabetes mellitus.